Can Pan-Immune inflammation value and systemic inflammatory response index be used clinically to predict inflammation in patients with non-small cell lung cancer
Yükleniyor...
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Kare Yayıncılık
Erişim Hakkı
info:eu-repo/semantics/embargoedAccess
Özet
Lung cancer is one of the most cancer type with the highest rate of cancer-related deaths in worldwide. Chronic inflammation has been associated with many diseases, including cancer, and the immune inflammatory re- sponse plays an important role in cancer patients. The aim of the study is to investigate the role of whether the pan- immune-inflammation value (PIV) and the systemic inflammatory response index (SIRI) are effective in predicting non- small lung cancer patients. Methods: In this retrospective case-control study, eighty-four patients and 71 healthy controls followed in Ordu State Hospital, Department of Medical Oncology from January 2020- to January 2023 were included. Results: White Blood Cell, Neutrophil, Hemoglobin , RDW, CRP were statistically significant between the study groups (p<0.05). A statistically significant difference was found between SII, SIRI, PIV, NLR, LMR and dNLR indices between the case and healthy subjects (p<0.05). However, there was no significant difference in PLR levels between the groups (p>0.05). Conclusion: We indicated that SIRI and PIV could be novel cost-effective biomarkers and treatment response precur- sors in patients with NSCLC.
Açıklama
Anahtar Kelimeler
Non-small Cell Lung Cancer, Inflammation, Systemic Inflammatory Response Index, Pan-immune-inflammation Value
Kaynak
Eurasian Journal of Medical Investigation
WoS Q Değeri
Scopus Q Değeri
Cilt
8
Sayı
1
